ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

SILO Silo Pharma Inc

1.9798
-0.3202 (-13.92%)
최종 업데이트: 23:15:05
15분 지연
기업명 주식 심볼 시장 주식 타입
Silo Pharma Inc SILO 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.3202 -13.92% 1.9798 23:15:05
개장가 저가 고가 종가 전일 종가
2.30 1.94 2.30 2.30
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
21/05/202421:45GLOBESilo Pharma Announces Positive Results from Study for..
14/05/202421:45GLOBESilo Pharma to Participate in FDA Meeting Exploring Emerging..
14/05/202405:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/04/202421:15GLOBESilo Pharma Announces Positive Results for Intranasal PTSD..
10/04/202421:11GLOBESilo Pharma set to Acquire Exclusive Licensing for Promising..
20/03/202421:30GLOBESilo Pharma Exercises Option for Exclusive License Agreement..
18/03/202420:15GLOBESilo Pharma Files Patent for Groundbreaking Ketamine Implant..
28/02/202422:25GLOBESilo Pharma Completes Successful Dose-Ranging Study of..
14/02/202422:45GLOBESilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful..
02/02/202403:15EDGAR2Form 8-K - Current report
02/02/202400:00GLOBESilo Pharma Announces Pipeline Prioritization for 2024..
31/01/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
26/01/202407:29EDGAR2Form S-3/A - Registration statement under Securities Act of..
26/01/202407:27EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/01/202422:55GLOBESilo Pharma Announces Positive Results in Alzheimer’s..
24/01/202407:01EDGAR2Form S-3 - Registration statement under Securities Act of..
12/01/202402:15EDGAR2Form 8-K/A - Current report: [Amend]
10/01/202406:30EDGAR2Form 8-K - Current report
04/01/202422:55GLOBESilo Pharma Successfully Completes First Phase of..
28/12/202322:25GLOBESilo Pharma and Partner Receive Regulatory Approval to Begin..
22/12/202306:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202306:58EDGAR2Form 8-K12B - Notification that a class of securities of..
19/12/202309:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202306:05EDGAR2Form 8-K - Current report
08/12/202308:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202306:05EDGAR2Form 8-K - Current report
05/12/202306:55EDGAR2Form 8-K - Current report
01/12/202311:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202307:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202322:01GLOBESilo Pharma Enters into Exclusive License Agreement with..
21/11/202309:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:11GLOBESilo Pharma to Initiate Dose-Ranging Study of Novel..
24/10/202306:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/10/202306:00EDGAR2Form DEF 14A - Other definitive proxy statements
16/10/202321:11GLOBESilo Pharma’s SPU-21 Peptide Shows Positive Results Against..
11/10/202321:35GLOBESilo Pharma Initiates Human Factor Study of SPC-15 for the..
11/10/202305:00EDGAR2Form PRE 14A - Other preliminary proxy statements
20/09/202321:28GLOBESilo Pharma Announces Positive Data on SPC-15 for PTSD and..
12/09/202321:50GLOBESilo Pharma Initiates Feasibility Study of SPC-15 Novel..
31/08/202320:30EDGAR2Form 8-K - Current report
12/08/202305:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202321:50GLOBESilo Pharma Engages Clarivate for Intellectual Property and..
08/08/202321:30GLOBESilo Pharma Reaches Positive Milestone with Nasal..
30/06/202305:31EDGAR2Form 8-K - Current report
21/06/202322:00GLOBESilo Pharma’s SPU-21 Treatment for Autoimmune Disease..
13/06/202321:05GLOBESilo Pharma Signs Agreement to Develop First-in-Class..
02/06/202321:50GLOBESilo Pharma Announces Participation on Webull Corporate..
30/05/202322:00GLOBESilo Pharma Commences Study of Novel Joint Homing Peptide..